Drug Profile
Umbralisib - TG Therapeutics
Alternative Names: RP 5307; RP-5264; TGR-1202; UKONIQLatest Information Update: 24 Jan 2024
Price :
$50
*
At a glance
- Originator Incozen Therapeutics; Rhizen Pharmaceuticals
- Developer TG Therapeutics Inc
- Class Amines; Antineoplastics; Benzopyrans; Fluorinated hydrocarbons; Ketones; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Casein kinase 1 epsilon inhibitors; Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic lymphocytic leukaemia
- Phase II/III Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
- Phase II Hodgkin's disease; Waldenstrom's macroglobulinaemia
- Phase I/II Non-Hodgkin's lymphoma
- No development reported Multiple sclerosis; Myelofibrosis; Polycythaemia vera; Richter's syndrome; Solid tumours
Most Recent Events
- 09 Dec 2023 Efficacy and adverse events data from a phase II trial in Chronic lymphocytic leukaemia presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 28 Mar 2023 National Cancer Institute terminates the phase II trial for Follicular lymphoma (Combination therapy, Second-line therapy or greater) in USA (NCT03269669)
- 28 Mar 2023 TG Therapeutics terminates phase II trial in Chronic lymphocytic leukemia (CLL) (Combination therapy, Second line therapy or greater) in USA due to strategic business decision (NCT04149821)